adenosine monophosphate has been researched along with Lymphocytopenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Diószegi, Á; Farkas, K; Hevessy, Z; Illés, Á; Magyari, F; Nagy, B; Nagy, G; Páyer, E; Pinczés, LI; Sik, M; Simon, Z; Ujfalusi, S | 1 |
| Cipriani, L; Forner, G; Furlan, A; Gherlinzoni, F; Rigoli, R; Scotton, P; Vian, E | 1 |
| Boerema, AS; Bouma, HR; Henning, RH; Ijzerman, A; Kok, JW; Kroese, FG; Mandl, JN; Strijkstra, AM; van Dam, A | 1 |
3 other study(ies) available for adenosine monophosphate and Lymphocytopenia
| Article | Year |
|---|---|
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Topics: Adenosine Monophosphate; Alanine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Hematologic Neoplasms; Humans; Immunization, Passive; Lymphopenia; Oxygen; SARS-CoV-2 | 2022 |
Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Topics: Adenosine Monophosphate; Alanine; B-Lymphocytes; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Administration Schedule; Humans; Immunization, Passive; Immunocompromised Host; Immunosuppressive Agents; Italy; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Pneumonia, Viral; Rituximab; SARS-CoV-2; Treatment Outcome | 2021 |
5'-AMP impacts lymphocyte recirculation through activation of A2B receptors.
Topics: Adenosine Monophosphate; Animals; Body Temperature Regulation; Calcium; Cell Movement; Flow Cytometry; Hibernation; Lymphocytes; Lymphopenia; Mice; Mice, Inbred C57BL; Receptor, Adenosine A2B | 2013 |